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Engineering of 3D regenerative skeletal muscle tissue constructs (skMTCs) using
hydrogels containing muscle precursor cells (MPCs) is of potential benefit for repairing
Volumetric Muscle Loss (VML) arising from trauma (e.g., road/industrial accident,
war injury) or for restoration of functional muscle mass in disease (e.g., Muscular
Dystrophy, muscle atrophy). Additive Biofabrication (AdBiofab) technologies make
possible fabrication of 3D regenerative skMTCs that can be tailored to specific
delivery requirements of VML or functional muscle restoration. Whilst 3D printing
is useful for printing constructs of many tissue types, the necessity of a balanced
compromise between cell type, required construct size and material/fabrication process
cyto-compatibility can make the choice of 3D printing a secondary alternative to
other biofabrication methods such as wet-spinning. Alternatively, wet-spinning is more
amenable to formation of fibers rather than (small) layered 3D-Printed constructs. This
study describes the fabrication of biosynthetic alginate fibers containing MPCs and their
use for delivery of dystrophin-expressing cells to dystrophic muscle in the mdx mouse
model of Duchenne Muscular Dystrophy (DMD) compared to poly(DL-lactic-co-glycolic
acid) copolymer (PLA:PLGA) topically-seeded with myoblasts. In addition, this study
introduces a novel method by which to create 3D layered wet-spun alginate skMTCs for
bulk mass delivery of MPCs to VML lesions. As such, this work introduces the concept
of “Trojan Horse” Fiber MTCs (TH-fMTCs) and 3d Mesh-MTCs (TH-mMTCs) for delivery
of regenerative MPCs to diseased and damaged muscle, respectively.
Keywords: alginate fibers, myoblasts, wet-spun, muscle engineering, biosynthetic muscle scaffold
INTRODUCTION
In absence of effective pharmaceutical treatments for the long-term functional restoration ofmuscle
tissue mass or function lost due to disease or trauma, numerous cell-based strategies have emerged
to improve regenerative outcomes in damaged and dysfunctional skeletal muscle (Emery, 2002).
These strategies include myoblast transfer therapies, growth factor delivery, stem cell delivery, gene
therapy, and combinations of each (Emery, 2002; Mendell et al., 2010; Gombotz and Wee, 2012;
Proto and Huard, 2013).
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While skeletal muscle is a regenerative tissue by comparison
with other soft tissues, regeneration is dependent on the
activation of a pool of satellite cells (SCs) from their quiescent
state, and in the case of larger traumas or degenerative
disease, this process is hindered, and medical intervention is
required. The function of the SCs is to initiate (in the response
to major injury) cell-based myoregeneration by proliferative
differentiation of muscle precursors that eventually fuse into
multi-nucleated myotubes, forming functional myofibres whilst
retaining a myoregenerative muscle precursor cell (MPC) niche
(Proto and Huard, 2013).
In degenerative myopathies such as the muscular dystrophies,
regenerative MPC loss occurs more rapidly than in non-
dystrophic muscle due to progressive myofibre degeneration
and removal from the functional niche. This places excessive
demand on the regenerative MPC pool to replace the
lost muscle fibers until the MPC pool is exhausted. This
regenerative/functional niche dynamic underpins the progressive
skeletal muscle weakness and volume loss characteristic to
the disease. By example, the X-linked congenital Duchenne’s
Muscular Dystrophy (DMD), is caused by mutation of the
gene encoding the cytoskeletal protein dystrophin results in a
lack of functional dystrophin (Mendell et al., 2010), resulting
in membrane destabilization and loss of muscle tissue (Blake
et al., 2002). This dystrophic process can be ameliorated by
implantation of dystrophin-expressing donor cells that fuse with
the host muscle and provide functional dystrophin. However,
past attempts at Myoblast Transplantation Therapy (MTT)
have had mixed success in dystrophic mdx mice but failed
in humans due to factors including (i) limited migration of
the cells from the injection site, (ii) immune rejection of the
cells by the host muscle, and (iii) general high-level post-
implant cell death. Corrective gene editing (cGE) Strategies
have been designed and successfully applied for editing out
the dystrophin gene mutation in vitro and in vivo (Kapsa
et al., 2001, 2003; Wong et al., 2005; Bengtsson et al.,
2017). These facilitate the possibility of providing autologous
myoregenerative cells with corrected dystrophin loci to restore
non-dystrophic functional/myoregenerative niche dynamics in
dystrophic muscle provided that cells can be effectively delivered
to the dystrophic muscle. In the case of volumetric muscle
loss (VML) injury, the situation is similarly dependent on
cell delivery/matrix technology that allows for myoregenerative
activity to be successfully localized to the VML lesion.
To be of clinical benefit, transplanted myoblasts must either
fuse with the host myofibres to or form de novo skeletal muscle
via fusion of the donor cells (Skuk et al., 2004, 2006, 2011).
The current “gold-standard” methodology for introduction of
regenerative cells to muscle involves Bolus injection. This is of
limited efficacy due to failure of donor cells to engraft away
from the injection site, as well as immune reaction toward
the donor cells (Skuk et al., 2004, 2006, 2011). This technique
has been attempted for the delivery of myoblast transfers and
stem cell doses to diseased muscle, and in many cases, studies
have used alginate as a protecting hydrogel for the donor cells
(Borselli et al., 2011). Other studies have examined the use of
thermoplastic implantable fiber structures which exploit their
linear nature in aiding the alignment of transplantedmyoblasts to
encourage myogenesis and eliminate difficulties with dystrophin
localization (Razal et al., 2009).
Alginate is an abundant, naturally occurring anionic
polysaccharide, harvested from marine brown algae or less
commonly, from bacterial sources (Augst et al., 2006; Draget
and Taylor, 2009; Lee and Mooney, 2012). It is a co-polymer
consisting of (1-4)-linked β-D-mannuronate (M) and its C-5
epimer α-L-guluronate (G) residues, covalently linked together
in varying sequences or blocks, typically homopolymer blocks
and poly-alternating sequence blocks (e.g., GGGG,MMMM, and
GMGM). Due to its biocompatibility, low toxicity and almost
temperature independent gelation in the presence of divalent
cations, alginate has been the subject of extensive investigation
in wound healing roles, in the transplantation of cells, and in the
delivery of pharmaceuticals and immobilized bioactive agents
(Gombotz and Wee, 2012; Lee and Mooney, 2012; Falzarano
et al., 2013).
Current high-level complexity possible in material design
of medical alginate structures has revived exploration into
biofabrication techniques for implantable alginate/cell construct
technologies. Several additive assembly techniques such as
nanofibrous electrospinning, microbead encapsulation, wet-
spinning, casting, and bioplotting or 3D printing have each
been studied as a means of encapsulating cells within alginate
constructs. Of these processes, wet-spinning is desirable due
to its high throughput for fiber production and as the output
mimics the linear geometric characteristics of native muscle.
Furthermore, wet spinning allows for bio-functional components
(including cells) to be deposited, woven or knitted into defined
structures with minimal effect to biological function (Chen
et al., 2009). In addition as with other additive biofabrication
technologies such as 3D printing, wet spinning facilitates
the precise placement within and release of bio-factors from
fibers, enabling more effective and reproducible fabrication
of functionally defined devices and structures (De Ruijter
et al., 2006; Mironov et al., 2009). Control of the processing
parameters during the fabrication of wet-spun fibers, such as
(in the case of alginates) the coagulation or non-solvent bath
concentration, the feedstock character and concentration and
draw rate (injection speed/collection spindle speed), can be
used to tune the throughput, porosity, and consistency of the
generated fibers (Qin, 2008; Peng et al., 2012).
Earlier studies by others (Hill et al., 2006; Borselli et al., 2011),
confirmed Alginate as being useful for delivery of regenerative
cells to muscle injury sites through compliance with base
requirements for successful re-engineering of damaged muscle
(Lee and Mooney, 2012). However, these studies applied cell-
laden alginate structures in “patch” formats covering VML
injuries to replace bulk muscle, but did not apply Alginate as
an intramuscular implant to restore dystrophin expression to
dystrophin-negative muscle.
This study applies Cell-laden Alginate “Trojan Horse”
structures implanted into dystrophic mdx mouse gastrocnemius
muscles to evaluate their potential to remodel dystrophic
muscle with dystrophin-expressing cells. In particular, this study
presents an optimized alginate/myoblast wet-spinning protocol
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alternative to 3D bioprinting. This protocol allows high-viability
encapsulation of muscle precursor cells (MPCs) within well-
characterized alginates as biocompatible fibers to form Trojan
Horse fiber muscle tissue constructs (fMTC) that hide the
introduced regenerative cells from host immune response. These
Trojan Horse fMTCs (TH-fMTCs) containing transgenic wild
type (i.e., non-dystrophic) β-Galactosidase-expressing mouse
myoblasts encapsulated within alginate fiber carriers, were
implanted into dystrophic (mdx) mouse muscle (mouse model
of DMD). This method of cell encapsulation within an alginate
hydrogel was compared to implantation of poly(DL-lactic-co-
glycolic acid) copolymer (PLA:PLGA) topically-seeded with
myoblasts or cells implanted by themselves as a cell bolus.
Applicability of the TH-fMTCs to replacement of bulk muscle
for VML injury was then further explored by in-process assembly
of TH-fMTCs into 3D Trojan Horse Mesh-MTC (TH-mMTC)
scaffolds using an additive wet-spinning approach.
MATERIALS AND METHODS
Materials
A buffer solution of 4-(2-hydroxyethyl)-1-piperazineethane
sulfonic acid (HEPES, Biochemical, #L505388) was made up to
a concentration of 308mM in a 20mM sodium chloride (NaCl)
solution. Alginic acid with sodium salt (Sigma, #035K0205)
was made to concentrations of 2 and 4% (wt/v) utilizing an
appropriate volume of distilled and autoclaved water at 60◦Cwith
stirring. Primary myoblasts were grown to 80% confluence in a
series of 30 T-75 flasks in 20ml of Dulbecco’s Modified Eagle’s
Medium (DMEM) at 37◦C. The cells were then trypsinised and
centrifuged at 280 g for 2min to pellet the cells. The cells were
then resuspended in HEPES solution to concentrations of 20,
40, and 60 million cells/ml. Mixing with corresponding alginate
solutions resulted in cell concentrations of 10, 20, and 30 million
cells/ml for both 1 and 2% (wt/v) alginate concentration.
Feedstock (Spinning Dope) Preparation
Alginate feedstocks containing no cells were made for myoblast-
loaded feedstocks: A buffer solution of 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, Biochemical, #L505388)
was made up to a concentration of 308 in a 20mM sodium
chloride (NaCl) solution. Alginate solutions were made to
concentrations of 2 and 4% (wt/v) utilizing an appropriate
volume of deionized and autoclaved water at 60◦C with stirring.
Cultured donor C57BL/10ScSnβ−Gal/SVHM (C57/
BL10Jβ−Gal; wild-type-βGal; wt-βGal) mouse myoblasts were
grown to 80% confluence in 20ml of Dulbecco’s Modified Eagle’s
Medium (DMEM) at 37◦C in a series of 30 T-75 flasks. The cells
were then trypsinised and centrifuged at 2,200 rpm for 2min
to pellet the cells. The cells were then resuspended in HEPES
solution to concentrations of 20, 40, and 60 million cells/ml.
Mixing with corresponding alginate solutions resulted in cell
concentrations of 10, 20, and 30 million cells/ml for both 1 and
2% (wt/v) alginate concentrations.
Donor Myoblast Cell Preparation
Male C57BL/10ScSnβ−Gal/SVHM mice, 5–6 week of age
were obtained (Bioresources Center, St. Vincent’s Hospital,
Melbourne, Australia), exposed to a 12 h day/night cycle and fed
ad-libitum until they were required for muscle culture. All animal
handling aspects of this study were carried out in accordance with
the recommendations of the Australian Code of Practice for the
Care of Animals for Scientific Purposes (NHMRC) as outlined
in protocol SVHM86/06 and approved by the St. Vincent’s
Hospital Animal Ethics Committee. After cervical dislocation,
skeletal muscle was removed from the hind limbs of the mice
and primary myoblast cultures prepared as described elsewhere
(Todaro et al., 2007).
Briefly, the muscle tissue was finely minced using scissors
and digested with 10mg ml−1 Collagenase D (Roche), 2.4U
ml−1 Dispase II (Roche), and 2.5mM CaCl2 for 2 h. The muscle
slurry was filtered through 70 and 40µm filters, respectively. Red
blood cells were lysed by 5min, room temperature incubation
with 17mM tris(hydroxymethyl)aminomethane and 144mM
ammonium chloride. The myoblast cultures were preplated once
for 20min, once for 40min, once for 2 h, and then at 24 h
intervals for the next 4 days in proliferationmedium consisting of
Hams/F10 (TRACE) supplemented with 20% fetal bovine serum
(Invitrogen), 2.5 ng ml−1 bFGF (PeproTech Asia), 2mM L-
glutamine (Invitrogen), 100U ml−1 of penicillin (Invitrogen),
and 100mgml−1 streptomycin (Invitrogen). Adherentmyoblasts
at preplate 9 were cultured in proliferation medium at 37◦C and
5% CO2 and passaged at >80% confluence.
Wet Spinning
A wet spinning arrangement as shown in Figures 1A,B was used
to fabricate cell-impregnated poly(DL-lactic-co-glycolic acid)
copolymer (PLA:PLGA) (Figures 1D,E) and alginate (Figure 1F)
Trojan Horse fibers. The unit consists of a digitally controlled,
four-beam stainless steel spindle, with outermost diameter of
40mm, and a second controller with a piston for directed fiber
output along a single axis.
For wet spinning cell-containing Alginate fibers, an aqueous
coagulation bath (L = 1m) of 2% calcium chloride (Sigma,
#48H0106) was used for cross-linking the fibers. Myoblasts
were encapsulated in Pronova ultra-pure low viscosity, high
guluronate sodium alginate (20–200 mPa.s for 2% w/w solution
at 25◦C,>60%G, ca. 75–200 kDa) obtained from Novamatrix for
all in vitro and in vivo experiments.
Prior to encapsulation, myoblasts were suspended in 2 x cell
buffer (300mM NaCl, 20mM HEPES) at a concentration of
60× 106, 40× 106, or 20 × 106 cells/ml. Cells were then mixed
with an equal volume of alginate solution (2 or 4% w/v in sterile
RO H2O) resulting in final cell concentrations of 30, 20, and
10× 106 cells/ml in 1 or 2% alginate. The alginate/cell mixtures
were extruded into a coagulation bath using a high precision
KD Scientific KDS-410 constant volume syringe pump at a rate
of 0.03ml min−1. A 30G EFD Nordson A rotating drum was
operated at a fixed velocity of 2 cm s−1 for the collection of fibers
following coagulation. The collected fibers were immediately
transferred to a solution of 154mM HEPES and 10mM NaCl to
avoid drying and cell damage.
For PLA:PLGA fibers, the same apparatus was used with
the modification that 20 wt % 75:25 PLA:PLGA (110,000
MW; 0.71 i.v.) suspended in chloroform was coagulated
(and washed) in isopropanol baths. The spinning solution
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FIGURE 1 | Wet-Spinning BioSynthetic Myoblast Fibers (PLGA and Alginate): Comparison of native Muscle, PLGA and “Trojan Horse” Alginate Fibers. (A) Apparatus.
(B) Line Schematic. (C) Native Muscle Fibers and myoblasts immunostained with Desmin: early culture. (D) PLGA Fibers with myoblasts and myotubes attached
externally (immunostained with Desmin). (E) SEM of PLGA fiber with myotubes attached. Myoblasts on the PLGA fibers were seen to spread and differentiate
longitudinally without evidence of retained proliferative capacity under differentiation conditions in vitro. (F) 1% Alg Trojan Horse Fibers with 2 × 107 myoblasts/ml
(longitudinal and cross sections inset, Hematoxylin and Eosin). Unless otherwise specified, size calibration markers are 100 µm.
injection and fiber collection rates were held, respectively, to
1.8ml/h and 8.5m/min as described elsewhere (Razal et al.,
2009). The resulting fibers were seeded with myoblasts 48 h
in Hams/F10 (TRACE) supplemented with 20% fetal bovine
serum (Invitrogen), 2.5 ng ml−1 bFGF (PeproTech Asia), 2mM
L-glutamine (Invitrogen), 100U ml−1 of penicillin (Invitrogen),
and 100mg ml−1 streptomycin (Invitrogen) before they were
implanted into mouse muscle.
To populate the PLGA fibers with cells, MPCs were grown ex
vivo on the PLGA fibers as described elsewhere (Razal et al., 2009)
for 7 days at which point they were detached from the substrate
for implantation into recipientmdx and wt mouse muscle.
Analysis of Biosynthetic Trojan Horse Fiber
Muscle Tissue Constructs (TH-fMTCs)
For viability and characterization, cell-bearing alginate biofibres
were collected into HEPES containing 1µM calcein AM in
DMSO and 1 µg ml−1 of propidium iodide (PI). An Olympus
IX70 fluorescence microscope was used at 10× magnification to
visualize fibers with varying cell densities (Figures 2A–C) and
to establish optimal Alginate concentration (Figure 2D) and cell
density (Figure 2E) for the alginate-based TH-fMTCs.
For quantification of DNA content within the fibers, a
PicoGreen assay was used. For each subgroup, five sets of twenty
10mm fibers were added to a microfuge tube containing 100
µL 0.1% wt v−1 Triton-X in PBS solution. For cryo-sectioning,
samples of fibers were embedded into Tissue-Tek Optimal
Cutting Temperature Compound and placed into a slurry of
dry ice and ethanol. These were stored at −70◦C before being
sectioned using a LEICA CM1900 Rapid Sectioning Cryostat.
In all analyses, four independent synthesis experiments
were evaluated to confirm/otherwise the repeatability of the
fabrication process. Finally, several fibers were collected into
both proliferation and differentiation media for visualization
of cell placement within the fibers and to establish biomimetic
support of key pro-myoregenerative behavior (proliferation,
Frontiers in Chemistry | www.frontiersin.org 4 February 2020 | Volume 8 | Article 18
Quigley et al. Alginate for Skeletal Muscle Engineering
FIGURE 2 | Optimization of BioSynthetic Alginate/Myoblast Trojan Horse Constructs for Implantation: Alg Fibers with: (A) 1 × 107 cells/ml; (B) 2 × 107 Cells/ml;
(C) 3 × 107 Cells/ml; (D) Controlled and consistent fiber diameter regardless of cell numbers or alginate concentration was achieved, with no statistical differences
evident between syntheses (t-test). (E) Cell Death (%Dead Cells) was evaluated in 1 and 2% alginate fibers loaded with 1, 2, and 3 × 107 Cells/ml to establish optimal
(Continued)
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FIGURE 2 | alginate/cell combination as evident by post-spun cell viability. A maximum of ∼15% of cells died as a result of wet-spinning in 1 and 2% alginate loaded
with 3 × 107 Cells/ml and in biosynthetic fiber constructs of 2% alginate loaded with 2 × 107 Cells/ml. This evaluation showed that 1% Alg/2 × 107 Cells/ml resulted
in the least numbers of cells entering programmed cell death as a result of the wet-spinning process. Statistical-significance markers for student t statistics shown are
as follows: *p < 0.05; **p < 0.01; ***p < 0.005. (F) Cells disperse inside the BioSynthetic 1% Alginate/2 × 107 myoblasts/ml Trojan Horse constructs in vitro, where
they (G) Proliferate freely until they (H) Migrate from the constructs into the surrounding environment and (I–K) Differentiate normally according to biological cues
within the environment. This biological behavior in vitro models the cell delivery dynamic expected when the cell-loaded alginate-based Trojan Horse constructs are
implanted into muscle. Unless otherwise specified, size calibration bars are 100µm. Optimization of PLGA/Cell fibers was limited to seeding cells on fibers at optimal
ex vivo cell plating density immediately prior to implantation. Unless otherwise specified, size calibration bars are 100 µm.
differentiation and migratory capabilities) of the cells
encapsulated within the alginate fMTCs (Figures 2G–K).
Surgical Implantation of Trojan Horse
Fibers and Cell Bolus Into mdx and wt
Muscle
C57BL/10ScSn/Arc (wild-type; wt) and C57BL/10ScSn-
Dmdmdx/Arc (X-Linked Muscular Dystrophy) male mice, 8–9
weeks of age were obtained from Animal Resources Center,
WA, exposed to a 12 h day/night cycle and fed ad-libitum
until they were required for surgery. All animal handling was
performed according to the St. Vincent’s Hospital Animal
Ethics Committee protocol 013/11, in accordance with the
Australian Code of Practice for the Care of Animals for Scientific
Purposes (NHMRC).
All surgical procedures were performed under anesthesia
using inhaled isofluorane (1% v:v, 1 L min−1 O2). The hind leg
fur was removed by shaving and 10µl of 5µg/ml notexin (Sigma-
Adlrich) was injected into the gastrocnemius muscle of both legs.
The following day the gastrocnemius muscles were exposed by an
incision through the skin. A 3–4mm deep, 5mm long incision
was made in the muscle parallel to the muscle fibers with a
scalpel blade. The incision was teased open with tweezers and
5mm long cell-laden alginate or PLA:PLGA fibers (∼5 × 105
cells) were placed inside (Figure 3A). The muscle was closed by
suturing the muscle fascia with a 6/0 silk suture (Dynek) and
the skin closed with 9mm wound clips (Becton Dickinson). All
mice received subcutaneous injection of (Carprofen, 5mg kg−1)
analgesic post-surgery.
Cell Bolus groups were injected with 1 × 106 cells suspended
in mouse-tonicity saline after the notexin treatment.
At selected post implantation analysis times, mice were
euthanized by cervical dislocation, and gastrocnemius muscles
removed. The muscles were snap frozen in liquid nitrogen-
cooled 2-methylbutane (Sigma-Aldrich) and stored at −70◦C
prior to analysis.
Muscles were cryosectioned by cutting 10µm serial cross-
sections through the entire length of the specimen to find
localization of donor (βGal+ve) cells.
Beta-Galactosidase (βGal) Staining
Cryosections were equilibrated to room temperature and fixed
in 0.5% gluteraldehyde in PBS (Sigma-Aldrich) for 5min at
room temperature. Sections were washed in three changes
of PBS and staining solution (2.5mM K3Fe(CN)6), 2.5mM
K4Fe(CN)6.3H20, 2mM MgCl2, 1mg ml
−1 X-Gal, 1× PBS pH
7.4) was applied. Sections were incubated overnight at 37◦C
in a humidified chamber. At completion of staining sections
were washed in two changes of distilled water and mounted
in aqueous mounting medium. In some cases, sections were
back-stained with Haematoxyllin and Eosin as described below
(Figures 3B,C,E,F). The specimens were visualized using an
Olympus IX-70 fluorescent microscope, and images were taken
using Spot Advanced 4.0.9 software.
Dystrophin Immunofluorescence
Cryosections were equilibrated to room temperature and rinsed
in phosphate buffered saline (PBS, pH 7.4). Sections were blocked
in 10% v/v donkey serum in PBS for 60min, then incubated
with either rabbit anti-dystrophin antibody (Santa Cruz) at 1:100
dilution in blocking solution for 60min at 37◦C, followed by
two washes with PBS. Secondary donkey anti-rabbit Alexa Fluor
488 (Molecular Probes) diluted 1:2,000 in blocking solution
was incubated for 60min at 37◦C. After two washes in PBS,
nuclei were stained with 1µg ml−1 DAPI (4,6-diamidino-2-
phenylindole dihydrochloride) (Sigma–Aldrich) for 5min and
the specimens mounted in Fluorescence Mounting Media
(DAKO). The specimens were visualized using an Olympus IX-
70 fluorescent microscope, and images were taken using Spot
Advanced 4.0.9 software (Figure 3D). Dystrophin positive fibers
were counted for PLGA (n = 5) and Alginate (n = 5) Trojan
Horse constructs as well as for cells injected as a cell Bolus (n= 4)
as shown in Figure 3G.
Hematoxylin and Eosin Staining
Cryosections were equilibrated to room temperature and
fixed in 10% Formalin (Sigma-Aldrich) for 5min at room
temperature. Sections were washed in tap water, stained with
Gills’ Hematoxylin (Sigma-Aldrich) for 30 s, rinsed in 30
immersions into tap water (water changes every 10 immersions),
stained in Alcoholic Eosin Y (Sigma-Aldrich) with 2 immersions,
rinsed in 30 immersions of tap water (3 water changes),
dehydrated in three changes of 100% ethanol and cleared in
xylene. Sections were mounted in DPX. The specimens were
visualized using an Olympus IX-70 fluorescent microscope, and
images were taken using Spot Advanced 4.0.9 software.
RESULTS
The fabrication process (Figures 1A,B) of PLGA (Figures 1D,E)
and alginate (Figure 1F) Trojan Horse fibers containing
myoblasts and subsequent biological viability of these fibers were
optimized in vitro by analysis of process parameters: PLGA fibers
were maximally over-grown with myoblasts immediately prior
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FIGURE 3 | Biosynthetic PLGA and alginate fiber and cell bolus implantation into dystrophic and damaged mouse muscle. (A) Experimental schematic for
implantation of biosynthetic cell/fiber constructs containing dystrophin and β-Galactosidase-expressing C57BL10/β-Gal mouse myoblasts into mdx and C57BL10J
mouse muscle. (B) Biosynthetic 1% Alginate Trojan Horse Fibers loaded with β-Gal transgenic C57BL10/β-Gal myoblasts (3 × 106 c/ml) were transplanted into
dystrophic C57BL10-mdx mouse (muscular dystrophy) muscle showed that donor cells that migrated into the surrounding muscle expressed both (blue) β-Gal
(Continued)
Frontiers in Chemistry | www.frontiersin.org 7 February 2020 | Volume 8 | Article 18
Quigley et al. Alginate for Skeletal Muscle Engineering
FIGURE 3 | (C) As well as (green) dystrophin (D) In the dystrophic mdx host muscle. (E) This behavior also occurred in non-dystrophic muscle, with β-Gal-positive
cells evident within the Trojan Horse construct and in fibers (Eosin/β-Gal-stained) of the surrounding muscle. (F) Myoblasts implanted on PLGA fibers did not survive
and the PLGA fibers were still intact within the recipient muscle at 4 weeks post-implantation, with the PLGA fibers remaining hard (H&E stain). This was evident even
at 3 months post implant. (G) Alginate Trojan Horse constructs yielded demonstrably more effective re-modeling of recipient dystrophic muscle with
dystrophin-expressing cells (p < 0.05; t) than either cell bolus or cells implanted on PLGA fibers. PLGA fibers implanted with cells attached yielded no donor cells
engrafted into the host muscle tissue at this timepoint (data not shown) and were discounted from further consideration as a cell delivery vehicle. Unless otherwise
specified, size calibration bars are 100 µm.
to further studies, whilst evaluation of alginate concentration
and cell-loading parameters reproducibly yielded 1% and 2%
alginate fibers containing large numbers of cells. PLGA/myoblast
constructs required no further evaluation/optimization. Cell
numbers in alginate Trojan Horse Fiber Mus were controlled by
material feed rate and handling methods, reliably yielding fibers
that contained between 1 and 3 × 107 cells (Figures 2A–C). The
fiber diameter was able to be controlled likewise via material feed
rate, to between ∼130 and 150µm, with an average diameter of
125µm regardless of incorporated cell loading density or alginate
(w/v) concentration (Figure 2D).
Cell loading density was evaluated by extraction of DNA from
the synthetic bio-fibers and quantification using PicoGreen assay
for nucleic acids and was shown to increase accordingly with
cell numbers suspended within the originating alginate solution.
Of the six configurations evaluated, cell viability (based on PI
infiltration assay) with respect to cell loading and percentage
(w/v) Alg, was highest in fiber configurations of 1% alginate
containing 20 million cells/ml (96 ± 1%) (Figure 2E). These
fibers were taken as optimal synthetic bio-fibers for subsequent
experiments. Fibers produced using 2% alginate as a matrix
material, while displaying similar fiber diameters, demonstrated a
lower cell viability and consistency compared to correspondingly
cell-loaded 1% alginate fibers (Figure 2E).
The synthetic Trojan Horse bio-fibers were modeled in
the first instance on native muscle fiber/myoblast structures
observed in early primary culture stages (Figure 1C) and
compared to PLGA/myoblast fiber constructs (Figures 1D,E) as
possible structures for regenerative cell delivery into muscle.
Histological evaluation of these cell-laden fibers showed that
the myoblasts were evenly distributed longitudinally along and
cross-dimensionally across the diameter of the alginate fibers
(Figure 1F), whilst the PLA:PLGA fibers (Figure 1D) showed
distinct similarity to native fiber explants (Figure 1C).
To see if these constructs could be used to deliver functional
cells to muscle tissues, optimized biosynthetic fiber constructs
containing transgenic C57BL10J-βGal mouse myoblasts in
alginate or on PLA:PLGA fibers were prepared for implantation
into mouse muscle (Figure 3A): Synthetic (alginate) bio-
fibers of ∼500µm diameter were wet-spun using 1% alginate
and myoblasts at a density of 3 × 105 cells/ml derived
from non-dystrophic, β-Gal-expressing C57BL10J-ScSnβGal mice
(Figure 2F). Well below the 20 × 106 cells/ml viability threshold
for 1% alginate fibers (Figure 2E), this low cell density facilitated
reliable inclusion of ∼3,000 cells per 5mm fiber implant for
(quantitative) tracking of post-transplantation cell fate within
the recipient muscle tissue. The use of the C57BL10J-βGal
mouse myoblasts provided an allogeneic donor cell source
that facilitated post-implantation tracking of implanted cells’
localization via the βGal transgene whilst the larger diameter
facilitated manageability of handling during surgery.
PLA:PLGA fibers of ∼130µm diameter were likewise seeded
with C57BL10J-βGal mouse myoblasts as previously described,
for implantation into the recipientmdxmouse muscle.
Prior to implantation, the synthetic alginate bio-fibers’ cell-
loading and viability were confirmed by microscopy (Figure 2E)
and the integrated cells’ ability to proliferate within the fibers
was confirmed over 7 days’ culture in vitro. This established that
myoblasts embedded in the alginate fibers could be expanded
to at least four-fold the original cell numbers over 7 days
(Figure 2G) to attain required cell numbers if necessary. The
myoblasts displayed the ability to migrate from the alginate fibers
and to proliferate (Figure 2H) and differentiate (Figures 2I–K)
within the in vitro culture environment, a precursor indication
of the fibers constructs’ expected biological behavior when
implanted into muscle. Likewise for the PLA:PLGA fibers
(Figure 1D). Cells seeded on PLA:PLGA fibers likewise retained
proliferative and migration abilities in vitro (data not shown).
The bio-synthetic constructs (5mm in length) were surgically
implanted into notexin myo-ablated gastrocnemius muscles of
C57BL10J ScSn (wt) and C57BL10J ScSnDMD (mdx) mice. These
fibers were left in the recipient mouse muscles for 1 and 2 weeks,
respectively, after which the mice were euthanized and the tissues
harvested for analysis of (i) cell survival within the constructs,
(ii) cell migration from the constructs into the host muscle, and
(iii) ability to remodel the host muscle with regenerative muscle
fibers derived from the donor cells.
Donor cells implanted in alginate Trojan Horse fMTCs
into both mdx (Figure 3D) and C57BL10J non-dystrophic
(Figure 3E) mouse muscles survived within the host tissue 4 and
2 2 and 1 week post implantation, respectively. In both dystrophic
and non-dystrophic environments, donor cells were evident both
within the boundary of the alginate fiber component in which
they had been implanted, as well as within the recipient mouse
muscle tissue. Serial sections of the biosynthetic fiber construct-
implanted mdx muscle showed that expression of the βGal
transgene from the non-dystrophic C57BL10J-ScSnβGal derived
donor myoblasts (Figures 3B,C) corresponded with dystrophin
expression from the donor myoblasts within the implanted mdx
muscle (Figure 3D). In addition, there were clear signs that
the alginate vehicle used to deliver the cells into the muscle
environment had begun to undergo degradation even after 1
week, in stark contrast to PLA:PLGA/myoblast fibers, which
were clearly evident as intact in recipient muscle after 12
weeks without cell survival and with significant foreign body
response (Figure 3F). These results suggest that in vitromyoblast
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proliferation in, and migration from a biosynthetic alginate/cell
construct with subsequent differentiation to muscle fibers within
the surrounding environment shown in vitro in Figures 2I–K
translate to cell behavior from within such constructs when
implanted into muscle tissue in vivo. On the other hand, the
lack of cell engraftment into host mdx muscle by cells seeded
on PLA:PLGA fMTCs indicates that this mode of delivery is
unsuitable for delivery of cells to muscle tissues, whilst the
alginate Trojan Horse-fMTC delivery method resulted in better
engraftment of recipient muscle with donor cells that bolus
injection of donor cell mass (Figure 3G).
DISCUSSION
Additive fabrication and assembly of functionalized fibers
produced by wet-spinning into implantable three dimensional
constructs presents attractive prospects for the field of
regenerative medical bionics (Wallace et al., 2012). In particular,
the incorporation of biologically active agents including growth
factors (Quigley et al., 2013a,b) and living cells (Chung et al.,
2013) within biocompatible and macroporous fibers that allow
for mass transfer and cell migration, is expected to deliver
improvements to cell and drug delivery platforms, particularly in
the area of tissue engineering biotechnology (Hong et al., 2006;
Lee et al., 2011).
This study investigated application of wet-spinning as an
alternative (to 3D printing) additive bio-fabrication technology
for generating three-dimensional cell-bearing (encapsulated and
topically-seeded) biosynthetic fibers containing live muscle
precursor cells (myoblasts) for remodeling damaged and
dystrophic muscle.
Our previous studies evaluated a cell transplantation approach
in which cells can be grown onto wet-spun fibers ex vivo
for subsequent implantation into muscle tissue as biosynthetic
fiber/cell structures. Razal et al. (2009) The cell-bearing fibers
from earlier applications using poly(DL-lactic-co-glycolic acid)
copolymer (PLA:PLGA) were shown here to be unsuitable
muscle remodeling due to prolonged hardness and subsequent
stimulation of fibrosis within the implanted muscle.
Subsequently, our long-standing use of sodium alginate (Alg)
hydrogel cross-linked with calcium for delivery of myotrophic
growth factors (Austin et al., 2000), identified Alg as a suitable
material for muscle (i.e., soft tissue) engineering applications. Alg
owes its suitability for such applications to its general physical
compliance with soft tissue target properties and its permissive
degradation profile that elicits minimal inflammatory response
and facilitates passive diffusion of oxygen and mass transport
(Qin, 2004; Berthiaume and Morgan, 2010).
In contrast to 3D bioprinting, which is somewhat limited to
short, usually hatch-like structures, the structural linearity of wet-
spun fibers mimics the linear characteristics of native muscle
structure. Furthermore, wet spinning allows functional materials
to be deposited, woven or knitted into defined structures
with minimal disruption of incorporated biological factors’ or
cells’ functional integrity (Chen et al., 2009). Perhaps most
importantly, wet spinning affords precise control of placement
and release of factors within and from the fibers, yielding more
effective and reproducible fabrication of functionally defined
devices and structures (De Ruijter et al., 2006; Mironov et al.,
2009).
Further development of the wet-spun fiber/myoblast
biosynthetic fiber system described here along these lines stands
to deliver a highly defined regenerative cell construct for the
repair and remodeling of damaged and diseased muscle that
yields superior engraftment compared to bolus-injections of cell
mass. In particular, refinement of the alginate component with
biofactors (e.g., extracellular matrix and/or growth proteins)
(Austin et al., 2000; Lee and Mooney, 2012) and possible pre-
conditioning of the cells to specific defined sub-phenotypes will
FIGURE 4 | 3D Matrix of BioSynthetic (Alg/Myoblast) Fibers. (A) Line
schematic of layer by layer (LbL) deposition of fibers to form a 3D
cell-containing mat. The process can be repeated additively with 90◦ rotation
of each subsequent deposition prior to collection until the required number of
layers are attained. Linearity of biosynthetic alginate/myoblast fibers can be
maintained by alternating layers of just alginate (no cells) in between layers of
alginate/myoblast fibers. (B) A 1cm × 1 cm × 0.625mm 3D 5-layer matrix
scaffold of (1% alginate/2 × 107 per ml myoblast) fibers prepared by LbL fiber
deposition as described in (A). (B′) The size of the entire 3D mesh scaffold
shown against a millimeter scale. (B′′) High resolution image of the mesh
muscle tissue constructs, with cells located within the individual fibers.
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potentiate the value of these biosynthetic constructs for muscle
engineering and repair.
A further point of refinement that better facilitates this
system’s application to tissue engineering is its translation to a
three-dimensional format. Toward this end, the linear collection
system outlined in Figure 1A was modified to incorporate a
layer by layer approach in which fiber collection was periodically
discontinued and resumed after a 90◦ adjustment of the
collection axis (Figure 4A). In this manner, a 5-layer mat of wet-
spun fibers containing cells was readily obtained (Figure 4B),
demonstrative of further applicability of wet spinning to the
construction of 3D myo-regenerative implants for applications
of volumetric muscle loss.
Collectively, the wet spinning of cells into biocompatible
fibers and subsequent formation of 3D structures from these
fibers as described in this study provides a new avenue by
which 3D muscle microtissues can be engineered ex-vivo for in
vitro experimentation modeling or for re-engineering injured
or diseased muscle. This layer by layer wet-spinning approach
mitigates some of the issues such as exposing cells to excessive
nozzle pressures evident in formation of such structures using
other additive fabrication technologies such as 3D bio-printing.
CONCLUSION
This work communicates the successful wet spinning of
biosynthetic alginate/myoblast Trojan Horse fiber muscle
tissue constructs (TH-fMTCs) composed of 1% alginate fibers
containing primary myoblasts at high cell concentrations.
The cells remained highly viable post-fabrication and it was
determined that the most efficient subgroup consisted of a
1% wt/v alginate matrix incorporating a cell concentration
of 2 × 107 cells ml−1. The myoblasts embedded within the
alginate fibers were shown to be proliferative in vitro and to
migrate from the fibers into the surrounding environment,
where they were able to undergo appropriate differentiation
into myotubes. These regenerative biological behaviors were
recapitulated in vivo by biosynthetic alginate/myoblast fiber
constructs containing primary allogeneic C57BL10J-ScSnβGal
myoblasts carrying a βGal reporter transgene, implanted into
myo-ablated non-dystrophic C57BL10J ScSn (wt) and dystrophic
C57BL10J ScSnDMD (mdx) mice. In these experiments, donor
cell-derived βGal reporter transgene expression detected in
muscle fibers outside of the alginate vehicle both in mdx and
wt mouse muscle, confirmed that some of the donor myoblasts
migrated from the biosynthetic fiber constructs, incorporated
into the surrounding muscle tissue network and formed donor-
derived muscle fibers. Importantly, co-expression of dystrophin
(denoting functional, fully differentiated non-dystrophic muscle
fibers normally absent inmdxmuscle) with βGal in serial sections
of the implanted mdx muscle highlighted that the biosynthetic
alginate/myoblast constructs could remodel dystrophin-negative
mdxmuscle tissue with dystrophin-producing fibers.
In considering the material/cell configuration to be used for
remodeling muscle tissue, the biosynthetic alginate/myoblast
system reported here resulted in more robust regenerative
results than did myoblasts attached to PLA:PLGA fibers,
which left intact PLA:PLGA fibers devoid of donor myoblasts
even 3 months after implantation. Likewise, the alginate
TH-fMTC configuration yielded better engraftment of
donor cells than did bolus-injected MPCs. These results
suggest that 3D “Trojan Horse” scaffolds composed of
biosynthetic soft gel alginate/myoblast fibers present an
attractive method by which to promote remodeling of diseased
and/or damaged muscle.
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